21892 Federal Register / Vol. 87, No. 71 / Wednesday, April 13, 2022 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Chris Kornak at 240–627–3705 or 

chris.kornak@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Humanized Murine Monoclonal 

Antibodies That Neutralize Type-1 

Interferon (IFN) Activity 

Description of Technology 

Interferons (IFNs) are a family of 

cytokines that function in response to 

an immune challenge such as a viral or 

bacterial infection. Type I IFNs are 

produced by immune cells 

(predominantly monocytes and 

dendritic cells) as well as fibroblasts 

and signal through a specific cell 

surface receptor complex (IFNAR) that 

consist of IFNAR1 and IFNAR2 chains. 

Type-I IFNs exert several common 

effects including antiviral, 

antiproliferative, and 

immunomodulatory activities. However, 

Type I IFNs also have pro-inflammatory 

effects, especially in the presence of 

TNF-a. Therefore, neutralizing the proinflammatory effect of Type I interferon 

could have wide clinical applications in 

autoimmune diseases like SLE, or in 

acute and chronic viral diseases like 

SARS–CoV–2, HIV or HCV infection, 

respectively, in which IFN-induced 

inflammation may be detrimental. 

Scientists at the National Institute of 

Allergy and Infectious Diseases (NIAID) 

have developed two anti-IFN receptor 2 

(IFNAR2) antibodies, B7 and A10, that 

are effective in vitro at neutralizing 

Type I IFN activities. The antibodies are 

comprised of two heavy chains and two 

light chains of amino acids. Both 

antibodies are able to bind to the 

extracellular domain of IFNAR2, Type I 

IFN receptor subunit 2, thus 

suppressing IFN signaling. 

Because there are no potent IFNAR2 

antibodies for therapies commercially 

available at this time, these antibodies 

are a novel therapeutic tool that could 

be used exclusively or in combination to 

treat chronic inflammatory diseases 

(like autoimmune disorders such as 

SLE) in which sustained IFN production 

may lead to both systemic and specific 

organ dysfunctions or chronic viral 

diseases (such as HIV, HCV) in which 

sustained IFN production has 

deleterious effects on immunologic 

function. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

Therapeutics for the treatment of 

chronic inflammatory conditions: 

• In chronic inflammatory diseases 

(e.g., autoimmune disorders such as 

SLE). 

• In chronic viral diseases (such as 

HIV, HCV infection). 

• In acute viral or inflammatory 

diseases (e.g., SARS–CoV–2). 

Development Stage 

• Pre-clinical. 

Inventors: Paolo Lusso, M.D. Ph.D., 

Hana Schmeisser, Ph.D., Kathryn C. 

Zoon, Ph.D., Qingbo, Liu, Ph.D., all of 

NIAID. 

Publications: 

A.N. Morrow, H. Schmeisser, T. Tsuno, K.C. 

Zoon. A novel role for IFN-stimulated 

gene factor 3II in IFN-g induction of 

antiviral activity in human cells. J 

Immunol 186: 1685–93, 2011. 

C.A. Balinsky, H. Schmeisser, S. Ganesan, K. 

Singh, T.C. Pierson, K.C. Zoon. 

Nucleolin interacts with the dengue 

virus capsid protein and plays a role in 

formation of infectious virus particles. J 

Virol 87: 13094–106, 2013. 

H. Schmeisser, S.B. Fey, J. Horowitz, E.R. 

Fischer, C.A. Balinsky, K. Miyake, J. 

Bekisz, A.L. Snow, K.C. Zoon. Type I 

interferons induce autophagy in certain 

human cancer cell lines. Autophagy 9: 

683–96, 2013. 

L.A. Zaritsky, J.R. Bedsaul, K.C. Zoon. Virus 

multiplicity of infection affects type I 

interferon subtype induction profiles and 

interferon-stimulated genes. J Virol 89 

(22): 11534–48, 2015. 

C.A. Balinsky, H. Schmeisser, A.I. Wells, S. 

Ganesan, T. Jin, K. Singh, K.C. Zoon. 

IRAV (FLJ112886), an interferon 

stimulated gene with antiviral activity 

against Dengue Virus, interacts with 

MOV 10. J Virol 14: 91(5), e01606–16, 

2017. 

A.W.T. Chiang, S. Li, B.P. Kellman, G. 

Chattopadhyay, Y. Zhang, Ch. Ch. Kuo, 

J.M. Gutierrez, F, Ghazi, H. Schmeisser, 

P. Me ́nard, S.P. Bj<rn, B.G. Voldborg, 

A.S. Rosenberg, M. Puig, Nathan E. 

Lewis. Combating viral contaminants in 

CHO cells by engineering innate 

immunity. Sci Rep 9 (1), 8827, 2019. 

Intellectual Property: HHS Reference 

No. E–220–2020–0; U.S. provisional 

application No. 63/094,572 filed on 

10/21/2020 and PCT application PCT/ 

US2021/056067. 

Licensing Contact: To license this 

technology, please contact Chris Kornak 

240–627–3705 or chris.kornak@nih.gov, 

and reference E–220–2020. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Chris Kornak at 240–627–3705 

or chris.kornak@nih.gov. 

Dated: April 8, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–07892 Filed 4–12–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development of 

Diagnostic for Imaging and Early 

Detection of Pancreatic Cancer and 

Pre-Cancerous Lesions by Targeting 

the Cholecystokinin-B Receptor 

AGENCY: National Institutes of Health. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an exclusive, sublicensable, 

patent license to Georgetown University 

‘‘Georgetown’’, a private university 

located in Washington DC, to its rights 

to the invention embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this notice. 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 71 / Wednesday, April 13, 2022 / Notices 21893 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before April 28, 2022 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Whitney Hastings, Ph.D., 

Senior Technology Transfer Manager at 

whitney.hastings2@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

United States Provisional Patent 

Application No. 63/030,815, filed May 

27, 2020, entitled ‘‘TARGETING THE 

CHOLECYSTOKININ–B RECEPTOR 

FOR IMAGING AND EARLY 

DETECTION OF PANCREATIC 

CANCER AND PRE–CANCEROUS 

LESIONS,’’ [HHS Ref. No. E—184– 

2020–0]. 

The patent rights in these inventions 

have been assigned to the Government 

of the United States of America and 

Georgetown University. The prospective 

patent license will be for the purpose of 

consolidating the patent rights to 

Georgetown, the co-owner of said rights, 

for commercial development and 

marketing. Consolidation of these coowned rights is intended to expedite 

development of the invention, 

consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212. 

The prospective patent license will be 

worldwide, exclusive, and may be 

limited to those fields of use 

commensurate in scope with the patent 

rights. It will be sublicensable, and any 

sublicenses granted by Georgetown will 

be subject to the provisions of 37 CFR 

part 401 and 404. 

This technology discloses a method of 

detecting the presence of a pancreatic 

intraepithelial neoplasia lesion in vivo 

via administering to the subject a 

construct, or a pharmaceutically 

acceptable salt thereof, wherein the 

construct is comprised of siRNApolymer nanoparticle complex that 

selectively bind to cholecystokinin-B 

receptors. The nanoparticle can be 

conjugated with a fluorophore or 

radioactive molecule (e.g., technetium). 

In conjunction with an imaging device, 

the polyplex nanoparticle could be used 

to detect the presence of precancerous 

pancreatic intraepithelial neoplasia 

(PanIN) lesions. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: April 7, 2022. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2022–07866 Filed 4–12–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIH 

HEAL Initiative: Preventing Opioid Misuse 

and Co-Occurring Conditions by Intervening 

on Social Determinants. 

Date: May 13, 2022. 

Time: 1:00 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Marisa Srivareerat, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Office of Extramural Policy, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 435–1258, 

marisa.srivareerat@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: April 7, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–07868 Filed 4–12–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2022–0160] 

National Merchant Marine Personnel 

Advisory Committee Meeting; May 

2022 Teleconference 

AGENCY: U.S. Coast Guard, Department 

of Homeland Security. 

ACTION: Notice of Federal advisory 

committee teleconference meeting. 

SUMMARY: The National Merchant 

Marine Personnel Advisory Committee 

(Committee) will meet via 

teleconference to discuss issues relating 

to personnel in the United States 

Merchant Marine including the training, 

qualifications, certification, 

documentation, and fitness of mariners. 

DATES: 

Meeting: The National Merchant 

Marine Personnel Advisory Committee 

will meet by teleconference on Tuesday, 

May 3, 2022, from 10:00 a.m. until 4:30 

p.m. (Eastern Daylight Time). The 

teleconference may adjourn early if the 

Committee has completed its business. 

Comments and supporting 

documentation: To ensure your 

comments are received by Committee 

members before the teleconference, 

submit your written comments no later 

than April 19, 2022. 

ADDRESSES: To join the teleconference 

or to request special accommodations, 

contact the individual listed in the FOR

FURTHER INFORMATION CONTACT section 

no later than 1 p.m. on April 19, 2022, 

to obtain the needed information. The 

number of individuals on a 

teleconference line is limited and will 


jspears on DSK121TN23PROD with NOTICES1